Milestone Scientific (MLSS) 10-Q 16 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 16, 2020
Document Information [Line Items]
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Entity Central Index Key	0000855683
Trading Symbol	mlss
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		63,693,469
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $.001 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,448,903	$ 1,516,272
Accounts receivable, net	962,983	1,710,665
Prepaid expenses and other current assets	527,059	519,063
Inventories, net	2,229,760	1,620,509
Advances on contracts	723,084	710,662
Total current assets	18,891,789	6,077,171
Furniture, fixtures and equipment, net	31,311	44,976
Patents, net	342,501	382,260
Right of use assets	655,870	15,977
Other assets	24,150	35,905
Total assets	19,945,621	6,556,289
Current liabilities:
Accounts payable	666,094	1,379,425
Accounts payable, related party	393,090	1,358,752
Accrued expenses and other payables	1,147,698	775,055
Accrued expenses, related party	593,625	1,057,958
Current portion of finance leases	7,903	3,904
Current operating lease right-of-use liabilities	68,934	12,072
Note payable	276,180
Deferred profit, related party	340,476	340,476
Total current liabilities	3,494,000	4,927,642
Finance lease liabilities, non-current	30,624
Operating lease right-of-use liabilities	576,407
Total liabilities	4,101,031	4,927,642
Commitments and contingencies
Stockholders’ equity
Common stock, par value $.001; authorized 75,000,000 shares; 63,605,119 shares issued and 63,571,786 shares outstanding as of September 30, 2020; 49,410,176 shares issued and 49,376,843 shares outstanding as of December 31, 2019;	63,605	49,410
Additional paid in capital	116,577,241	96,082,324
Accumulated deficit	(99,806,352)	(93,524,297)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific Inc. stockholders' equity	15,922,978	1,695,921
Noncontrolling interest	(78,388)	(67,274)
Total stockholders’ equity	15,844,590	1,628,647
Total liabilities and stockholders’ equity	$ 19,945,621	$ 6,556,289

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	63,605,119	49,410,176
Common stock, shares outstanding (in shares)	63,571,786	49,376,843
Treasury stock, at cost, shares (in shares)	33,333	33,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Product sales, net	$ 1,246,110	$ 1,899,821	$ 3,225,170	$ 6,073,580
Cost of products sold	409,621	523,672	1,024,947	1,894,550
Gross profit	836,489	1,376,149	2,200,223	4,179,030
Selling, general and administrative expenses	2,291,779	2,314,943	8,221,359	6,941,964
Research and development expenses	21,438	7,940	237,089	109,815
Total operating expenses	2,313,217	2,322,883	8,458,448	7,051,779
Loss from operations	(1,476,728)	(946,734)	(6,258,225)	(2,872,749)
Interest expense	(569)	(2,449)	(8,727)	(6,067)
Change in fair value of derivative liability		(1,899,484)		(1,846,761)
Loss before provision for income taxes and net of equity investments	(1,477,297)	(2,848,667)	(6,266,952)	(4,725,577)
Provision for income taxes	(24,717)	(1,250)	(26,217)	(19,877)
Loss before equity in net earnings (losses) of equity investments	(1,502,014)	(2,849,917)	(6,293,169)	(4,745,454)
Earnings from China Joint Venture				49,099
Net loss	(1,502,014)	(2,849,917)	(6,293,169)	(4,696,355)
Net loss attributable to noncontrolling interests	11,025	12,941	35,501	35,343
Net loss attributable to Milestone Scientific Inc.	$ (1,490,989)	$ (2,836,976)	$ (6,257,668)	$ (4,661,012)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.02)	$ (0.06)	$ (0.11)	$ (0.11)
Diluted (in dollars per share)	$ (0.02)	$ (0.06)	$ (0.11)	$ (0.11)
Weighted average shares outstanding and to be issued—
Basic (in shares)	65,817,132	47,721,732	56,478,151	43,311,984
Diluted (in shares)	65,817,132	47,721,732	56,478,151	43,311,984

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Consultant [Member]Preferred Stock [Member]	Consultant [Member]Common Stock [Member]	Consultant [Member]Additional Paid-in Capital [Member]	Consultant [Member]Retained Earnings [Member]	Consultant [Member]Noncontrolling Interest [Member]	Consultant [Member]Treasury Stock [Member]	Consultant [Member]	Board of Directors [Member]Preferred Stock [Member]	Board of Directors [Member]Common Stock [Member]	Board of Directors [Member]Additional Paid-in Capital [Member]	Board of Directors [Member]Retained Earnings [Member]	Board of Directors [Member]Noncontrolling Interest [Member]	Board of Directors [Member]Treasury Stock [Member]	Board of Directors [Member]	Public Offering [Member]Preferred Stock [Member]	Public Offering [Member]Common Stock [Member]	Public Offering [Member]Additional Paid-in Capital [Member]	Public Offering [Member]Retained Earnings [Member]	Public Offering [Member]Noncontrolling Interest [Member]	Public Offering [Member]Treasury Stock [Member]	Public Offering [Member]	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]Noncontrolling Interest [Member]	Private Placement [Member]Treasury Stock [Member]	Private Placement [Member]	April 6, 2020 Public Offering [Member]Preferred Stock [Member]	April 6, 2020 Public Offering [Member]Common Stock [Member]	April 6, 2020 Public Offering [Member]Additional Paid-in Capital [Member]	April 6, 2020 Public Offering [Member]Retained Earnings [Member]	April 6, 2020 Public Offering [Member]Noncontrolling Interest [Member]	April 6, 2020 Public Offering [Member]Treasury Stock [Member]	April 6, 2020 Public Offering [Member]	June 30, 2020 Public Offering [Member]Preferred Stock [Member]	June 30, 2020 Public Offering [Member]Common Stock [Member]	June 30, 2020 Public Offering [Member]Additional Paid-in Capital [Member]	June 30, 2020 Public Offering [Member]Retained Earnings [Member]	June 30, 2020 Public Offering [Member]Noncontrolling Interest [Member]	June 30, 2020 Public Offering [Member]Treasury Stock [Member]	June 30, 2020 Public Offering [Member]	The 2019 Warrants [Member]Preferred Stock [Member]	The 2019 Warrants [Member]Common Stock [Member]	The 2019 Warrants [Member]Additional Paid-in Capital [Member]	The 2019 Warrants [Member]Retained Earnings [Member]	The 2019 Warrants [Member]Noncontrolling Interest [Member]	The 2019 Warrants [Member]Treasury Stock [Member]	The 2019 Warrants [Member]	The 2016 Warrants [Member]Preferred Stock [Member]	The 2016 Warrants [Member]Common Stock [Member]	The 2016 Warrants [Member]Additional Paid-in Capital [Member]	The 2016 Warrants [Member]Retained Earnings [Member]	The 2016 Warrants [Member]Noncontrolling Interest [Member]	The 2016 Warrants [Member]Treasury Stock [Member]	The 2016 Warrants [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018																																																									7,000	36,329,600
Balance at Dec. 31, 2018																																																									$ 7	$ 36,330	$ 88,414,718	$ (85,999,929)	$ (11,402)	$ (911,516)	$ 1,528,208
Stock based compensation																																																											56,988				56,988
Common stock issued to employee for compensation (in shares)																																																										22,727
Common stock issued to employee for compensation																																																										$ 23	7,477				7,500
Common stock to be issued for payment of consulting services (in shares)		118,115
Common stock to be issued for payment of consulting services		$ 118	$ 39,882				$ 40,000
Common stock to be issued to employees for bonuses (in shares)																																																										175,715
Common stock to be issued to employees for bonuses																																																										$ 175	61,325				61,500
Net loss																																																												(782,752)	(10,443)		(793,195)
Common stock issued for payment of consulting services (in shares)									20,588
Common stock issued for payment of consulting services									$ 21	$ 6,979				$ 7,000
Common stock issued in offering (in shares)																6,282,400							714,286
Common stock issued in offering																$ 6,281	$ 1,968,265				$ 1,974,546		$ 714	$ 249,286				$ 250,000
Reclassification of warrants and Shares to be issued to derivative liability (Note 9)																																													$ (406,045)				$ (406,045)
Balance (in shares) at Mar. 31, 2019																																																									7,000	43,663,431
Balance at Mar. 31, 2019																																																									$ 7	$ 43,662	90,398,875	(86,782,681)	(21,845)	(911,516)	2,726,502
Balance (in shares) at Dec. 31, 2018																																																									7,000	36,329,600
Balance at Dec. 31, 2018																																																									$ 7	$ 36,330	88,414,718	(85,999,929)	(11,402)	(911,516)	1,528,208
Net loss																																																															(4,696,355)
Balance (in shares) at Sep. 30, 2019																																																										48,199,074
Balance at Sep. 30, 2019																																																										$ 48,199	90,166,259	(90,660,941)	(46,745)	(911,516)	(1,404,744)
Balance (in shares) at Mar. 31, 2019																																																									7,000	43,663,431
Balance at Mar. 31, 2019																																																									$ 7	$ 43,662	90,398,875	(86,782,681)	(21,845)	(911,516)	2,726,502
Stock based compensation																																																											44,712				44,712
Common stock issued to employee for compensation (in shares)																																																										41,667
Common stock issued to employee for compensation																																																										$ 42	14,958				15,000
Common stock to be issued for payment of consulting services		$ 265	139,735				140,000
Net loss																																																												(1,041,284)	(11,959)		(1,053,243)
Common stock issued for payment of consulting services (in shares)		265,140							82,442
Common stock issued for payment of consulting services									$ 82	29,918				30,000
Reclassification of warrants and Shares to be issued to derivative liability (Note 9)																																												$ (2,902)	(1,062,637)				(1,065,539)
Conversion of Preferred Shares to Common Stock (Mandatory) (in shares)																																																									(7,000)	5,982,906
Conversion of Preferred Shares to Common Stock (Mandatory)																																																									$ (7)	$ 5,983	(5,976)
Reclassification of warrants and Shares to be issued to derivative liability (Note 9) (in shares)																																												(2,903,366)
Balance (in shares) at Jun. 30, 2019																																																										47,132,220
Balance at Jun. 30, 2019																																																										$ 47,132	89,559,585	(87,823,965)	(33,804)	(911,516)	837,432
Stock based compensation																																																											45,147				45,147
Common stock issued to employee for compensation (in shares)																																																										18,072
Common stock issued to employee for compensation																																																										$ 18	14,982				15,000
Common stock to be issued for payment of consulting services (in shares)		202,325
Common stock to be issued for payment of consulting services		$ 202	113,298				113,500
Common stock to be issued to employees for bonuses (in shares)																																																										170,454
Common stock to be issued to employees for bonuses																																																										$ 170	149,830				150,000
Common stock issued for warrants (in shares)																																																										57,750
Common stock issued for warrants																																																										$ 58	28,817				28,875
Net loss																																																												(2,836,976)	(12,941)		(2,849,917)
Common stock issued for payment of consulting services (in shares)		316,824							44,408
Common stock issued for payment of consulting services		$ 317	122,683				123,000		$ 44	29,956				30,000
Reclassification of warrants and Shares to be issued to derivative liability (Note 9)																																												$ (435)	$ (308,065)				$ (308,500)		$ 693	$ 410,026				$ 410,719
Reclassification of warrants and Shares to be issued to derivative liability (Note 9) (in shares)																																												(435,260)							692,281
Balance (in shares) at Sep. 30, 2019																																																										48,199,074
Balance at Sep. 30, 2019																																																										$ 48,199	90,166,259	(90,660,941)	(46,745)	(911,516)	(1,404,744)
Balance (in shares) at Dec. 31, 2019																																																										49,410,176
Balance at Dec. 31, 2019																																																										$ 49,410	96,082,324	(93,524,297)	(67,274)	(911,516)	1,628,647
Stock based compensation																																																											30,715				30,715
Common stock issued to employee for compensation (in shares)																																																										22,633
Common stock issued to employee for compensation																																																										$ 23	14,989				15,012
Common stock to be issued for payment of consulting services (in shares)
Common stock to be issued for payment of consulting services			25,000				25,000
Common stock to be issued to employees for bonuses (in shares)
Common stock to be issued to employees for bonuses																																																											171,046				171,046
Common stock issued for warrants (in shares)																																																										460,725
Common stock issued for warrants																																																										$ 460	229,902				230,362
Net loss																																																												(1,600,215)	(12,738)		(1,612,953)
Balance (in shares) at Mar. 31, 2020																																																										49,893,534
Balance at Mar. 31, 2020																																																										$ 49,893	96,553,976	(95,124,512)	(80,012)	(911,516)	487,829
Balance (in shares) at Dec. 31, 2019																																																										49,410,176
Balance at Dec. 31, 2019																																																										$ 49,410	96,082,324	(93,524,297)	(67,274)	(911,516)	1,628,647
Net loss																																																															(6,293,169)
Balance (in shares) at Sep. 30, 2020																																																										63,605,119
Balance at Sep. 30, 2020																																																										$ 63,605	116,577,241	(99,806,352)	(78,388)	(911,516)	15,844,590
Balance (in shares) at Mar. 31, 2020																																																										49,893,534
Balance at Mar. 31, 2020																																																										$ 49,893	96,553,976	(95,124,512)	(80,012)	(911,516)	487,829
Stock based compensation																																																											23,946				23,946
Common stock issued to employee for compensation (in shares)																																																										11,450
Common stock issued to employee for compensation																																																										$ 11	14,989				15,000
Common stock to be issued to employees for bonuses (in shares)
Common stock to be issued to employees for bonuses																																																											462,504				462,504
Common stock issued for warrants (in shares)																																																										620,750
Common stock issued for warrants																																																										$ 621	718,029				718,650
Net loss																																																												(3,166,464)	(11,738)		(3,178,202)
Common stock issued for payment of consulting services (in shares)		278,581							39,233
Common stock issued for payment of consulting services		$ 279	381,520				381,799		$ 39	53,967				54,006
Common stock issued to employees for bonuses (in shares)																																																										202,617
Common stock issued to employees for bonuses																																																										$ 203	(203)
Common stock issued in offering (in shares)																														5,420,000							6,770,000
Common stock issued in offering																														$ 5,420	$ 4,621,022				$ 4,626,442		$ 6,770	$ 13,410,074				$ 13,416,844
Acquired controlling interest in Milestone Advanced Cosmetic Systems																																																												(24,387)	24,387
Balance (in shares) at Jun. 30, 2020																																																										63,236,165
Balance at Jun. 30, 2020																																																										$ 63,236	116,239,824	(98,315,363)	(67,363)	(911,516)	17,008,818
Stock based compensation																																																											18,392				18,392
Common stock issued to employee for compensation (in shares)																																																										7,692
Common stock issued to employee for compensation																																																										$ 8	14,992				15,000
Common stock to be issued to employees for bonuses (in shares)																																																										180,272
Common stock to be issued to employees for bonuses																																																										$ 180	9,422				9,602
Common stock issued for warrants (in shares)																																																										52,500
Common stock issued for warrants																																																										$ 52	36,699				36,751
Net loss																																																												(1,490,989)	(11,025)		(1,502,014)
Common stock issued for payment of consulting services (in shares)		112,140							16,350
Common stock issued for payment of consulting services		$ 113	$ 227,928				$ 228,041		$ 16	$ 29,984				$ 30,000
Balance (in shares) at Sep. 30, 2020																																																										63,605,119
Balance at Sep. 30, 2020																																																										$ 63,605	$ 116,577,241	$ (99,806,352)	$ (78,388)	$ (911,516)	$ 15,844,590

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (6,293,169)	$ (4,696,355)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	35,103	37,159
Amortization of patents	39,759	39,760
Stock compensation	76,611	146,847
Employees paid in stock	768,463	315,425
Expense paid in stock	644,865	292,915
Non-cash operating lease expense	30,175
Earnings on China joint venture		(49,099)
Change in fair value of derivative liability		1,846,761
Changes in operating assets and liabilities:
Decrease in accounts receivable	747,682	739,195
Decrease in accounts receivable, related party		100,000
Decrease in other assets	11,755	(9,027)
(Increase) decrease in inventories	(609,251)	303,989
(Increase) decrease in advances on contracts	(12,422)	20,289
Decrease (Increase) in prepaid expenses and other current assets	(7,996)	(90,362)
(Decrease) in accounts payable	(713,331)	(465,670)
(Decrease) in accounts payable, related party	(965,662)	(109,989)
Decrease in deferred cost, related party		50,000
Increase (decrease) in accrued expenses	431,917	(50,428)
(Decrease) increase in accrued expenses, related party	(530,659)	402,905
(Decrease) in deferred revenue, related party		(100,000)
Net cash used in operating activities	(6,346,160)	(1,275,686)
Cash flows from investing activities:
Purchase of property and equipment	(21,438)	(9,916)
Net cash used in investing activities	(21,438)	(9,916)
Cash flows from financing activities:
Proceeds from exercise of warrants	985,763	28,875
Payments finance lease obligations	(4,998)
Net proceeds from note payable	276,180
Net proceeds from Public Placement Offering	18,043,284	1,974,547
Net proceeds from Private Placement Offering		250,000
Net cash provided by financing activities	19,300,229	2,253,422
Net increase in cash and cash equivalents	12,932,631	967,820
Cash and cash equivalents at beginning of period	1,516,272	743,429
Cash and cash equivalents at end of period	14,448,903	1,711,249
Supplemental non-cash disclosure of cash flow information:
Shares issued to board of directors		67,000
Shares issued to employees for compensation		37,500
Shares issued to consultants in lieu of cash payments		416,500
Shares issued to employee for bonuses		211,500
Credit from United Systems for defective handpieces		(151,562)
Initial recognition of operating lease-right of use assets	(706,071)	(166,292)
Initial recognition of operating lease right to used liabilities	$ 706,071	$ 166,292

Note 1 - Organization and Busin

Note 1 - Organization and Business	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 All references in this report to “Milestone Scientific, Inc.,” “us,” “our,” “we,” the “Company “or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Inc. and Milestone Medical Inc. and affiliate, Milestone Education LLC, unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDent CompuMed CompuFlo DPS Dynamic Pressure Sensing technology Milestone Scientific CathCheck the Milestone logo Safety Wand STA Single Tooth Anesthesia System The Wand Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand® CompuDent®, STA Single Tooth Anesthesia System® CompuMed®. CompuDent® CompuMed® 60 During 2016, 510 CompuFlo June 2017, CompuFlo eleven In December 2016, 510 not 510 April 2017, 510 510 January 2019. 510 2020. September 30, 2020, 510 19 2021. On April 21, 2020, On October 13, 2020, 4,100 200,000 November 1, 2020, February 28, 2022.

Note 2 - Liquidity and Uncertai

Note 2 - Liquidity and Uncertainties	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 AND UNCERTAINTIES The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one In the second 2020 two April June 2020, $4.6 $13.4 9 September 30, 2020, $14.4 $13 December 31, 2019. two The coronavirus (COVID- 19 December 2019 third 19, three nine September 30, 2020 Although there has been a slow pick up in dental instrument and disposable sell through to dentists beginning in the third 19 may fourth third

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 1. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation. 2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2019, 10 3. Certain reclassification has been made to the 2019 2020 no 4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. 5. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for customer arrangements the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights and the Company's historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 11 three nine September 30, 2020 2019. 6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. Because Milestone Scientific has a variable interest in Milestone China it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity's economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone Scientific does not not not 810. 6. 7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three may 8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not September 30, 2020, December 31, 2019, $10,000. 9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first not 10. Investments in which Milestone Scientific can exercise significant influence, but do not may 11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven 12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized based on the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost. 13. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results, ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. 14. On April 27, 2020, $276,000, March 27, 2020. The Loan, which was in the form of a Note dated April 27, 2020, April 27, 2022, 1.00% November 26, 2020. may no may February 15, 2020. may 15. Research and development costs, which consist principally of new product development costs payable to third 16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. On September 30, 2020 December 31, 2019, no No 2016, 2017, 2018 17. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses in the three nine September 30, 2020 2019, not 7,477,171 5,004,415 September 30, 2020 2019, 18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may September 30, 2020 not 19. The Company does not December 31, 2019. 815, 9, 20. Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718 21. At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Finance and operating lease right-of-use assets represent the Company's right to use an underlying asset over the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. These assets and obligations are recognized at the lease commencement date based on the present value of lease payments, net of incentives, over the lease term. The interest rate implicit in our leases is typically not We evaluate the classification of our leases as either finance leases or operating leases. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise, the leases are classified as operating leases. Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12 22. In June 2016, No. 2016 13, 326 December 15, 2022. not In August 2018, 2018 13, 820 820. 1 2 3 3 2018 13 December 15, 2019, not In August 2018, 2018 15, 350 40 2018 15 December 15, 2019, not In December 2019, 2019 12, 740 2019 12 December 15, 2020. not In January 2020, 2020 01, 321 323 815 2020 01 December 15, 2021, In August 2020, 2020 06, 470 20 815 40 2020 06 December 15, 2021, not

Note 4 - Inventories

Note 4 - Inventories	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 Inventories consist of the following: September 30, 2020 December 31, 2019 Dental finished goods, net $ 1,705,519 $ 1,306,763 Medical finished goods, net 169,549 213,861 Component parts and other materials 354,692 99,885 Total inventories $ 2,229,760 $ 1,620,509 On September 30, 2020, $450,000 $7,000. December 31, 2019, $450,000 $318,000. $311,000 December 31, 2019 nine September 30, 2020.

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE 5 The advances on contracts represent funding of future STA inventory purchases, epidural instruments, and epidural replacements parts. The balance of the advances as of September 30, 2020 December 31, 2019 $723,000 $710,000,

Note 6 - Investment in and Tran

Note 6 - Investment in and Transactions with Equity Investees	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 6 Milestone China Ltd. Ownership In June 2014, $1 forty 40% 75% In first 2020, 19 28.4% Related Party Transactions Milestone China is Milestone Scientific's exclusive distributor in China. During 2017 2018, 2018, $2.8 $950,000 $1.25 fourth 2018. For the three nine September 30, 2020 not three nine September 30, 2019 not zero $100,000 United System Agreement In April 2020, 13 2018, not $370,260 $100,000 April 2020, $170,260 April 23, 2020, $1.59 June 2020, $100,000 July 2020. $1.4 The Company has recorded a charge to the unaudited condensed consolidated statement of operations for $370,260 nine September 30, 2020. Milestone Advanced Cosmetic Systems Inc. Transaction In May 2020, 50% $900,000 50% one $900,000 100% Gross Profit Deferral Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third 323 40% third At September 30, 2020 December 31, 2019, $340,476 three nine September 30, 2020 2019 $0 $0 $0 $49,099 third Equity Method Disclosures As a result of the COVID- 19 not not three nine September 30, 2020. not not Milestone Scientific, in previous years, reduced its investment in Milestone China to zero $4.3 December 31, 2019, three nine September 30, 2020 not not

Note 7 - Patents

Note 7 - Patents	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 7 September 30, 2020 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,035,362 ) $ 342,501 Total $ 1,377,863 $ (1,035,362 ) $ 342,501 December 31, 2019 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (995,603 ) $ 382,260 Total $ 1,377,863 $ (995,603 ) $ 382,260 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 20 $13,000 $40,000 three nine September 30, 2020, $13,000 $40,000 three nine September 30, 2019,

Note 8 - Note Payable

Note 8 - Note Payable	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Effect of COVID-19 Pandemic [Text Block]	NOTE 8 On April 27, 2020, $276,000, March 27, 2020. 2.5 seven eight April 27, 2022 1.00% November 26, 2020. April 27, 2022 not may no may February 15, 2020.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9— PUBLIC OFFERING AND PRIVATE PLACEMENT February 2019, $2.0 5,715,000 1,428,750 5 $0.50 $198,000 567,400 141,850 Also, in February 2019, $250,000 714,286 178,571 Bp4 Bp4's 5 $0.50 In the second 2020, two April 2020, $5.1 5,420,000 2,710,000 $0.95 $1.20 three 3 June 2020, second $14.6 6,770,000 3,749,000 $2.15 $2.60 three 3 WARRANTS The following table summarizes information about shares issuable under warrants outstanding as of September 30, 2020 : Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2020 1,074,171 $ 0.50 $ 4.10 956,012 Issued 6,459,000 2.01 3.00 - Exercised (1,133,975 ) 0.87 - - Expired or cancelled - - - - Outstanding and exercisable at September 30, 2020 6,399,196 $ 1.95 $ 2.73 880,449 The following table summarizes information about shares issuable under warrants outstanding as of September 30, 2019 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2019 1,592,775 $ 2.55 $ 0.21 - Issued 1,749,171 0.50 4.35 560,199 Exercised (57,750 ) 0.50 - - Expired or cancelled - - - - Outstanding and exercisable at September 30, 2019 3,284,196 $ 1.49 $ 2.30 560,199 PREFERRED STOCK In May 2014, $10 $3 two million $1.50 $7 7,000 $1,000 $2.545, May 14, 2019. These shares were mandatory convertible on May 14, 2019, $2.54 $1.50 not $3.15 On May 14, 2019, $1.17 5,982,906 SHARES TO BE ISSUED As of September 30, 2020 2019, 2,202,229 2,294,734 As of September 30, 2020, 2019, 149,498 351,612 The following table summarizes information about shares to be issued on September 30, 2020 2019, September 30, 2020 September 30, 2019 Shares-to-be-issued, outstanding January 1, 2020 and 2019, respectively 2,375,762 2,470,566 Granted in current period 363,956 1,392,460 Issued in current period (387,991 ) (1,216,680 ) Shares-to be issued outstanding September 30, 2020 and 2019, respectively 2,351,727 2,646,346 OUTSTANDING EQUITY INSTRUMENTS IN EXCESS OF AUTHORIZED SHARES As a result of the shares and warrants issued in the public and private offerings as well as other issuance of common stock during 2019, not September 30, 2019, The initial fair value of the warrants was determined using a Black-Scholes option pricing model. The following assumptions were used to value the warrants at the reclassification date in 2019: 2016 Warrants 2019 Warrants Fair Value of Common Stock $.36- $.83 $ 0.33 Expected Term (years) .25-.5 years 4.9 years Volatility 86% 100% 83 % Dividend yield 0 % 0 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 1.88% 2.09% 2.30 % Weighted average fair value of warrants granted $ - $ 0.19 Number of shares underlying warrants granted 1,512,067 1,749,171 On the date of issuance and reclassification the fair value of the warrants was approximately $376,000. As these warrants are liability-classified, they were revalued on September 30, 2019 2016 Warrants 2019 Warrants Fair Value of Common Stock $ 0.83 $ 0.08 Expected Term (years) .02 years 4.4 years Volatility 86 % 86 % Dividend yield 0 % 0 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 1.88 % 1.55 % Weighted average fair value of warrants granted $ - 61.00 % Number of shares underlying warrants granted $ 1,512,067 $ 1,691,421 For the three nine September 30, 2019 $680,542 $674,792, Additionally, approximately 2.6 $0.83 September 30, 2019 ) three nine September 30, 2019 $1.2 On December 17, 2019, 75,000,000. December 17, 2019, no nine September 30, 2020.

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 10 The utilization of Milestone Scientific's net operating losses may 382 may 100%

Note 11 - Segment and Geographi

Note 11 - Segment and Geographic Data	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Product Sales and Significant Customers and Vendors Disclosure [Text Block]	NOTE 11 We conduct our business through two not The following tables present information about our reportable and operating segments: Net Sales: Three months ended September 30,2020 Three months ended September 30, 2019 Nine months ended September 30,2020 Nine months ended September 30, 2019 Dental $ 1,240,110 $ 1,884,321 $ 3,209,370 $ 6,042,580 Medical 6,000 15,500 15,800 31,000 Total net sales $ 1,246,110 $ 1,899,821 $ 3,225,170 $ 6,073,580 Operating Income (Loss): Three months ended September 30,2020 Three months ended September 30, 2019 Nine months ended September 30,2020 Nine months ended September 30, 2019 Dental $ 191,235 $ 644,650 $ (32,624 ) $ 1,766,087 Medical (812,840 ) (554,843 ) (2,297,080 ) (1,711,184 ) Corporate (855,123 ) (1,036,541 ) (3,928,521 ) (2,927,652 ) Total operating loss $ (1,476,728 ) $ (946,734 ) $ (6,258,225 ) $ (2,872,749 ) Depreciation and Amortization Three months ended September 30, 2020 Three months ended September 30, 2019 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Dental $ 402 $ 3,950 $ 9,202 $ 11,875 Medical 674 2,424 5,006 7,424 Corporate 15,429 19,044 60,653 57,620 Total depreciation and amortization $ 16,505 $ 25,418 $ 74,861 $ 76,919 Income (loss) before taxes and equity in earnings of affiliates: Three months ended September 30, 2020 Three months ended September 30, 2019 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Dental $ 190,472 $ 645,442 $ (35,376 ) $ 1,765,475 Medical (813,935 ) (556,969 ) (2,300,243 ) (1,713,362 ) Corporate (853,834 ) (2,937,140 ) (3,931,333 ) (4,777,690 ) Total loss before taxes and equity in earnings of affiliate $ (1,477,297 ) $ (2,848,667 ) $ (6,266,952 ) $ (4,725,577 ) Total Assets: September 30, 2020 December 31, 2019 Dental $ 5,391,842 $ 5,008,324 Medical 977,160 590,727 Corporate 13,576,619 957,238 Total assets $ 19,945,621 $ 6,556,289 The following table presents information about our operations by geographic area for three September 30, 2020 2019. Three months ended September 30, 2020 Three months ended September 30, 2019 Dental Medical Total Dental Medical Total Domestic-US Devices $ 34,657 $ - $ 34,657 $ 199,926 $ - $ 199,926 Handpieces 356,566 - 356,566 679,621 - 679,621 Other 16,906 - 16,906 17,343 - 17,343 Total Domestic US $ 408,129 $ - $ 408,129 $ 896,890 $ - $ 896,890 international Devices $ 220,694 $ - $ 220,694 $ 412,819 $ - $ 412,819 Handpieces 602,000 6,000 608,000 564,265 15,500 579,765 Other 9,287 9,287 10,347 - 10,347 Total International $ 831,981 $ 6,000 $ 837,981 $ 987,431 $ 15,500 $ 1,002,931 International-China Devices $ - $ - $ - $ - $ - $ - Handpieces - - - - - - Other - - - - - Total International $ - $ - $ - $ - $ - $ - Total Product Sales $ 1,240,110 $ 6,000 $ 1,246,110 $ 1,884,321 $ 15,500 $ 1,899,821 The following table presents information about our operations by geographic area for the nine September 30, 2020 2019. Nine months ended September 30, 2020 Nine months ended September 30, 2019 Dental Medical Total Dental Medical Total Domestic-US & Canada Devices $ 35,181 $ - $ 35,181 $ 398,729 $ 10,800 $ 409,529 Handpieces 992,057 2,000 994,057 2,250,542 300 2,250,842 Other 37,895 - 37,895 61,408 - 61,408 Total Domestic US & Canada $ 1,065,133 $ 2,000 $ 1,067,133 $ 2,710,679 $ 11,100 $ 2,721,779 International ROW Devices $ 494,998 $ 7,600 $ 502,598 $ 1,100,488 $ 8,000 $ 1,108,488 Handpieces 1,618,524 6,200 1,624,724 2,028,750 11,500 2,040,250 Other 30,715 - 30,715 102,663 400 103,063 Total International-ROW $ 2,144,237 $ 13,800 $ 2,158,037 $ 3,231,901 $ 19,900 $ 3,251,801 International-China Devices $ - $ - $ - $ - $ - $ - Handpieces - - - 100,000 - 100,000 Other - - - - - Total International $ - $ - $ - $ 100,000 $ - $ 100,000 Total Product Sales $ 3,209,370 $ 15,800 $ 3,225,170 $ 6,042,580 $ 31,000 $ 6,073,580

Note 12 - Concentrations

Note 12 - Concentrations	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 12 Milestone Scientific has informal arrangements with third September 30, 2020 December 31, 2019. For the three nine September 30, 2020, 40% 45% three nine September 30, 2019 54% 51%, two $720,000 74% 60% 14% September 30, 2020, one 77%, December 31, 2019. The COVID- 19 second third may 19 no may may may 19

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 13 United Systems Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $373,000 $549,000 three September 30, 2020 2019, $1,200,000 $1,100,000 nine September 30, 2020 2019, September 30, 2020 December 31, 2019, $365,000 $943,000, February 2019, 285,714 $0.35 $100,000 July 2019. April 29, 2020, $370,260 6. Milestone China As of September 30, 2020, 40% 6. Other As of September 30, 2020, December 31, 2019, $308,000 $380,000, August 2016, $25,000 $75,000 three nine September 30, 2020, 2019, In January 2017, twelve twelve $20,000 $60,000 three nine September 30, 2020, 2019, September 30, 2020. $61,000 $92,000 three September 30, 2020 2019, $158,000 $292,000 nine September 30, 2020 2019, $39,000 $117,000 three nine September 30, 2020 2019, September 30, 2020 December 31, 2019, $80,000 $390,000,

Note 14 - Commitments

Note 14 - Commitments	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 14 ( 1 third September 30, 2020, $515,284 $350,311 In August 2019, 100 2020. September 30, 2020, $299,000 100 $161,000 July 2020, 110 November 2020. September 30, 2020, $30,395 110 $21,195 ( 2 Operating Leases In June 2015, 774 January 31, 2020 $12,522. not not not In August 2019, not seven 7 January 8, 2020. April 1, 2020 January 1 $9,275 $10,898 $2.00 $11,130 not As of September 30, 2020, $655,870 $645,341, $68,934 $576,407 December 31, 2019, $15,977 $15,977. nine September 30, 2020, five $43,242. September 30, 2020, $38,527, $7,903 $30,624 Cash flow information related to the Company's right-of-use assets and related lease liabilities were as follows: Three months ended September 30, Nine months ended September 30, Lease cost 2020 2019 2020 2019 Cash paid for operating lease liabilities 30,820 39,555 78,904 118,664 Cash paid for finance lease liabilities 2,658 - 7,622 - Right-of-use assets obtained in exchange for new operating lease liabilities (1) - - 663,009 - Property and equipment obtained in exchange for new finance lease liabilities - 43,242 - (1) For the nine months ended September 30, 2019, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2019. Weighted-average remaining lease term - operating leases (years) - - 6.5 0.4 Weighted-average remaining lease term- finance leases (years) - - 4.3 - ( 3 The technology underlying the Safety Wand CompuFlo CompuDent January 1, 2005. 2.5% 5% third 13

Note 15 - Subsequent Events

Note 15 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 15— Since the quarter ended September 30, 2020, 8,000 $1.20 $9,600. The Company engaged Gian Domenico Trombetta, former CEO of Wand Dental Inc. as a consultant to Leonard Osser, Interim – Chief Executive Officer of Milestone Scientific for a period of twelve October 1, 2020 September 30, 2021). twelve $60,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2019, 10
Reclassification, Comparability Adjustment [Policy Text Block]	3. Certain reclassification has been made to the 2019 2020 no
Use of Estimates, Policy [Policy Text Block]	4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Revenue [Policy Text Block]	5. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for customer arrangements the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights and the Company's historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 11 three nine September 30, 2020 2019.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. Because Milestone Scientific has a variable interest in Milestone China it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity's economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone Scientific does not not not 810. 6.
Cash and Cash Equivalents, Policy [Policy Text Block]	7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three may
Accounts Receivable [Policy Text Block]	8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not September 30, 2020, December 31, 2019, $10,000
Inventory, Policy [Policy Text Block]	9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first not
Equity Method Investments [Policy Text Block]	10. Investments in which Milestone Scientific can exercise significant influence, but do not may
Property, Plant and Equipment, Policy [Policy Text Block]	11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized based on the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	13. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results, ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.
Debt, Policy [Policy Text Block]	14. On April 27, 2020, $276,000, March 27, 2020. The Loan, which was in the form of a Note dated April 27, 2020, April 27, 2022, 1.00% November 26, 2020. may no may February 15, 2020. may
Research and Development Expense, Policy [Policy Text Block]	15. Research and development costs, which consist principally of new product development costs payable to third
Income Tax, Policy [Policy Text Block]	16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. On September 30, 2020 December 31, 2019, no No 2016, 2017, 2018
Earnings Per Share, Policy [Policy Text Block]	17. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses in the three nine September 30, 2020 2019, not 7,477,171 5,004,415 September 30, 2020 2019,
Fair Value of Financial Instruments, Policy [Policy Text Block]	18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may September 30, 2020 not
Derivatives, Policy [Policy Text Block]	19. The Company does not December 31, 2019. 815, 9,
Share-based Payment Arrangement [Policy Text Block]	20. Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718
Lessee, Leases [Policy Text Block]	21. At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Finance and operating lease right-of-use assets represent the Company's right to use an underlying asset over the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. These assets and obligations are recognized at the lease commencement date based on the present value of lease payments, net of incentives, over the lease term. The interest rate implicit in our leases is typically not We evaluate the classification of our leases as either finance leases or operating leases. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise, the leases are classified as operating leases. Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12
New Accounting Pronouncements, Policy [Policy Text Block]	22. In June 2016, No. 2016 13, 326 December 15, 2022. not In August 2018, 2018 13, 820 820. 1 2 3 3 2018 13 December 15, 2019, not In August 2018, 2018 15, 350 40 2018 15 December 15, 2019, not In December 2019, 2019 12, 740 2019 12 December 15, 2020. not In January 2020, 2020 01, 321 323 815 2020 01 December 15, 2021, In August 2020, 2020 06, 470 20 815 40 2020 06 December 15, 2021, not

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2020 December 31, 2019 Dental finished goods, net $ 1,705,519 $ 1,306,763 Medical finished goods, net 169,549 213,861 Component parts and other materials 354,692 99,885 Total inventories $ 2,229,760 $ 1,620,509

Note 7 - Patents (Tables)

Note 7 - Patents (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2020 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,035,362 ) $ 342,501 Total $ 1,377,863 $ (1,035,362 ) $ 342,501 December 31, 2019 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (995,603 ) $ 382,260 Total $ 1,377,863 $ (995,603 ) $ 382,260

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2020 1,074,171 $ 0.50 $ 4.10 956,012 Issued 6,459,000 2.01 3.00 - Exercised (1,133,975 ) 0.87 - - Expired or cancelled - - - - Outstanding and exercisable at September 30, 2020 6,399,196 $ 1.95 $ 2.73 880,449 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2019 1,592,775 $ 2.55 $ 0.21 - Issued 1,749,171 0.50 4.35 560,199 Exercised (57,750 ) 0.50 - - Expired or cancelled - - - - Outstanding and exercisable at September 30, 2019 3,284,196 $ 1.49 $ 2.30 560,199
Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]	September 30, 2020 September 30, 2019 Shares-to-be-issued, outstanding January 1, 2020 and 2019, respectively 2,375,762 2,470,566 Granted in current period 363,956 1,392,460 Issued in current period (387,991 ) (1,216,680 ) Shares-to be issued outstanding September 30, 2020 and 2019, respectively 2,351,727 2,646,346
Schedule of Warrant or Right Outstanding and Options, Valuation Assumptions [Table Text Block]	2016 Warrants 2019 Warrants Fair Value of Common Stock $.36- $.83 $ 0.33 Expected Term (years) .25-.5 years 4.9 years Volatility 86% 100% 83 % Dividend yield 0 % 0 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 1.88% 2.09% 2.30 % Weighted average fair value of warrants granted $ - $ 0.19 Number of shares underlying warrants granted 1,512,067 1,749,171 2016 Warrants 2019 Warrants Fair Value of Common Stock $ 0.83 $ 0.08 Expected Term (years) .02 years 4.4 years Volatility 86 % 86 % Dividend yield 0 % 0 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 1.88 % 1.55 % Weighted average fair value of warrants granted $ - 61.00 % Number of shares underlying warrants granted $ 1,512,067 $ 1,691,421

Note 11 - Segment and Geograp_2

Note 11 - Segment and Geographic Data (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net Sales: Three months ended September 30,2020 Three months ended September 30, 2019 Nine months ended September 30,2020 Nine months ended September 30, 2019 Dental $ 1,240,110 $ 1,884,321 $ 3,209,370 $ 6,042,580 Medical 6,000 15,500 15,800 31,000 Total net sales $ 1,246,110 $ 1,899,821 $ 3,225,170 $ 6,073,580 Operating Income (Loss): Three months ended September 30,2020 Three months ended September 30, 2019 Nine months ended September 30,2020 Nine months ended September 30, 2019 Dental $ 191,235 $ 644,650 $ (32,624 ) $ 1,766,087 Medical (812,840 ) (554,843 ) (2,297,080 ) (1,711,184 ) Corporate (855,123 ) (1,036,541 ) (3,928,521 ) (2,927,652 ) Total operating loss $ (1,476,728 ) $ (946,734 ) $ (6,258,225 ) $ (2,872,749 ) Depreciation and Amortization Three months ended September 30, 2020 Three months ended September 30, 2019 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Dental $ 402 $ 3,950 $ 9,202 $ 11,875 Medical 674 2,424 5,006 7,424 Corporate 15,429 19,044 60,653 57,620 Total depreciation and amortization $ 16,505 $ 25,418 $ 74,861 $ 76,919 Income (loss) before taxes and equity in earnings of affiliates: Three months ended September 30, 2020 Three months ended September 30, 2019 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Dental $ 190,472 $ 645,442 $ (35,376 ) $ 1,765,475 Medical (813,935 ) (556,969 ) (2,300,243 ) (1,713,362 ) Corporate (853,834 ) (2,937,140 ) (3,931,333 ) (4,777,690 ) Total loss before taxes and equity in earnings of affiliate $ (1,477,297 ) $ (2,848,667 ) $ (6,266,952 ) $ (4,725,577 ) Total Assets: September 30, 2020 December 31, 2019 Dental $ 5,391,842 $ 5,008,324 Medical 977,160 590,727 Corporate 13,576,619 957,238 Total assets $ 19,945,621 $ 6,556,289
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three months ended September 30, 2020 Three months ended September 30, 2019 Dental Medical Total Dental Medical Total Domestic-US Devices $ 34,657 $ - $ 34,657 $ 199,926 $ - $ 199,926 Handpieces 356,566 - 356,566 679,621 - 679,621 Other 16,906 - 16,906 17,343 - 17,343 Total Domestic US $ 408,129 $ - $ 408,129 $ 896,890 $ - $ 896,890 international Devices $ 220,694 $ - $ 220,694 $ 412,819 $ - $ 412,819 Handpieces 602,000 6,000 608,000 564,265 15,500 579,765 Other 9,287 9,287 10,347 - 10,347 Total International $ 831,981 $ 6,000 $ 837,981 $ 987,431 $ 15,500 $ 1,002,931 International-China Devices $ - $ - $ - $ - $ - $ - Handpieces - - - - - - Other - - - - - Total International $ - $ - $ - $ - $ - $ - Total Product Sales $ 1,240,110 $ 6,000 $ 1,246,110 $ 1,884,321 $ 15,500 $ 1,899,821 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Dental Medical Total Dental Medical Total Domestic-US & Canada Devices $ 35,181 $ - $ 35,181 $ 398,729 $ 10,800 $ 409,529 Handpieces 992,057 2,000 994,057 2,250,542 300 2,250,842 Other 37,895 - 37,895 61,408 - 61,408 Total Domestic US & Canada $ 1,065,133 $ 2,000 $ 1,067,133 $ 2,710,679 $ 11,100 $ 2,721,779 International ROW Devices $ 494,998 $ 7,600 $ 502,598 $ 1,100,488 $ 8,000 $ 1,108,488 Handpieces 1,618,524 6,200 1,624,724 2,028,750 11,500 2,040,250 Other 30,715 - 30,715 102,663 400 103,063 Total International-ROW $ 2,144,237 $ 13,800 $ 2,158,037 $ 3,231,901 $ 19,900 $ 3,251,801 International-China Devices $ - $ - $ - $ - $ - $ - Handpieces - - - 100,000 - 100,000 Other - - - - - Total International $ - $ - $ - $ 100,000 $ - $ 100,000 Total Product Sales $ 3,209,370 $ 15,800 $ 3,225,170 $ 6,042,580 $ 31,000 $ 6,073,580

Note 14 - Commitments (Tables)

Note 14 - Commitments (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lease, Cost and Other Information [Table Text Block]	Three months ended September 30, Nine months ended September 30, Lease cost 2020 2019 2020 2019 Cash paid for operating lease liabilities 30,820 39,555 78,904 118,664 Cash paid for finance lease liabilities 2,658 - 7,622 - Right-of-use assets obtained in exchange for new operating lease liabilities (1) - - 663,009 - Property and equipment obtained in exchange for new finance lease liabilities - 43,242 - (1) For the nine months ended September 30, 2019, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2019. Weighted-average remaining lease term - operating leases (years) - - 6.5 0.4 Weighted-average remaining lease term- finance leases (years) - - 4.3 -

Note 1 - Organization and Bus_2

Note 1 - Organization and Business (Details Textual)	Sep. 30, 2020
Number of Countries in which Entity Operates	60

Note 2 - Liquidity and Uncert_2

Note 2 - Liquidity and Uncertainties (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Proceeds from Issuance of Common Stock			$ 18,043,284	$ 1,974,547
Cash and Cash Equivalents, at Carrying Value, Ending Balance			14,448,903		$ 1,516,272
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total			$ 12,932,631	$ 967,820
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 4,600,000
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock	$ 13,400,000

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Apr. 27, 2020USD ($)	Sep. 30, 2020shares	Sep. 30, 2020USD ($)shares	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Number of Operating Segments			2
Accounts Receivable, Allowance for Credit Loss, Ending Balance				$ 10,000	$ 10,000
Proceeds from Notes Payable, Total			$ 276,180
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares		7,477,171	5,004,415
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 276,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			2 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			7 years

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Slow Moving Medical Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance		$ 450,000	$ 450,000
Slow Moving Dental Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance		$ 7,000	$ 318,000
Inventory Write-down	$ 311,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Component parts and other materials	$ 354,692	$ 99,885
Total inventories	2,229,760	1,620,509
Dental Segment [Member]
Finished goods, net	1,705,519	1,306,763
Medical Segment [Member]
Finished goods, net	$ 169,549	$ 213,861

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts (Details Textual) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Advances on Inventory Purchases	$ 723,084	$ 710,662

Note 6 - Investment in and Tr_2

Note 6 - Investment in and Transactions with Equity Investees (Details Textual) - USD ($)	May 31, 2020	Apr. 29, 2020	Jul. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Apr. 23, 2020	Jun. 30, 2014
Accounts Receivable, Allowance for Credit Loss, Ending Balance					$ 10,000		$ 10,000	$ 10,000
Share Price (in dollars per share)					$ 0.83		$ 0.83
Income (Loss) from Equity Method Investments, Total							$ 49,099
Acquisition of Advanced Cosmetic Systems [Member]
Business Acquisition, Percentage of Voting Interests Acquired	50.00%
Business Combination, Consideration Transferred, Total	$ 900,000
Business Combination, Percentage of Ownership Interest that Seller of Ownership Interest May Repurchase Within One Year of Sale Date	50.00%
Business Combination, Price at Which the Additional Ownership Interest Acquired May Repurchased Within One Year of Sale Date	$ 900,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total	100.00%
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party		$ 370,260		$ 373,000	549,000	$ 1,200,000	1,100,000
Sale Price in Cash [Member]
Related Party Transaction, Purchases from Related Party		100,000	$ 100,000
Sale Price in Share [Member]
Related Party Transaction, Purchases from Related Party		$ 170,260
Share Price (in dollars per share)											$ 1.59
Milestone China [Member]
Equity Method Investments												$ 1,000,000
Equity Method Investment, Ownership Percentage				40.00%		40.00%						40.00%
Financing Receivable, after Allowance for Credit Loss, Total									$ 2,800,000
Proceeds from Collection of Finance Receivables									950,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance									$ 1,250,000
Revenue from Related Parties				$ 0	0	$ 0	0
Contract with Customer, Liability, Revenue Recognized					0		100,000
Due from Related Parties, Total				1,400,000		1,400,000
Costs and Expenses, Related Party						370,260
Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage									40.00%
Income (Loss) from Equity Method Investments, Total				0	$ 0	0	$ 49,099
Cost-method Investments, Realized Losses								4,300,000
Milestone China [Member] | Accounts Receivable from Related Parties [Member]
Equity Method Investment, Deferred Intercompany Profit (Loss)				$ 340,476		$ 340,476		$ 340,476
Milestone Beijing [Member] | Milestone China [Member]
Equity Method Investment, Ownership Percentage												75.00%
Anhui [Member] | Forecast [Member]
Equity Method Investment, Ownership Percentage										28.40%

Note 7 - Patents (Details Textu

Note 7 - Patents (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Amortization of Intangible Assets, Total	$ 13,000	$ 13,000	$ 39,759	$ 39,760
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			3 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			20 years

Note 7 - Patents - Summary of P

Note 7 - Patents - Summary of Patents (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Patents, cost	$ 1,377,863	$ 1,377,863
Patents, impairment	(1,035,362)	(995,603)
Patents, accumulated amortization	342,501	382,260
Foundation Intellectual Property Patents [Member]
Patents, cost	1,377,863	1,377,863
Patents, impairment	(1,035,362)	(995,603)
Patents, accumulated amortization	$ 342,501	$ 382,260

Note 8 - Note Payable (Details

Note 8 - Note Payable (Details Textual) - USD ($)	Apr. 27, 2020	Sep. 30, 2020	Sep. 30, 2019
Proceeds from Notes Payable, Total		$ 276,180
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 276,000

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) $ / shares in Units, xbrli-pure in Thousands	Jun. 30, 2020USD ($)$ / sharesshares	May 14, 2019$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Apr. 30, 2020USD ($)$ / sharesshares	Feb. 28, 2019USD ($)$ / sharesshares	May 31, 2014USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2019$ / sharesshares	Dec. 17, 2019shares	Jun. 30, 2019$ / shares	Dec. 31, 2018$ / sharesshares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.95		$ 0.50		$ 1.49	$ 2.55
Proceeds from Issuance of Private Placement | $					$ 250,000	$ 10,000,000			$ 250,000
Share Price (in dollars per share) | $ / shares							$ 0.83		$ 0.83
Proceeds from Issuance of Common Stock | $								$ 18,043,284	$ 1,974,547
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)							2,646,346	2,351,727	2,646,346	2,375,762			2,470,566
Class of Warrant or Right, Reclassified During Period (in shares)									376,000
Gain (Loss) on Issuance of Shares to be Issued | $							$ (680,542)		$ (674,792)
Derivative Instruments Not Designated as Hedging Instruments, Gain | $							$ 1,200,000		$ 1,200,000
Common Stock, Shares Authorized (in shares)								75,000,000		75,000,000	75,000,000
Derivative, Number of Instruments Held, Total								0
Common Stock, Shares, To be Issued (in shares)							2,600,000		2,600,000
Chief Executive Officer, Chief Financial Officer and Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)							2,294,734	2,202,229	2,294,734
Non-Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)							351,612	149,498	351,612
Preferred Stock Converted to Common Stock [Member]
Conversion of Stock, Conversion Price (in dollars per share) | $ / shares		$ 1.17
Conversion of Stock, Shares Issued (in shares)		5,982,906
Warrants, Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,428,750
Warrants and Rights Outstanding, Term (Year)					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.50
Underwrite Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					141,850
Warrants, Private Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					178,571
Warrants and Rights Outstanding, Term (Year)					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.50
Warrants Associated With April 2020 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,710,000
Warrants and Rights Outstanding, Term (Year)				3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 1.20
Warrants Associated With the June 2020 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,749,000		3,749,000
Warrants and Rights Outstanding, Term (Year)	3 years		3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.60		$ 2.60
Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $					$ 2,000,000
Stock Issued During Period, Shares, New Issues (in shares)					5,715,000
Proceeds from Stock Options Exercised | $					$ 198,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)					567,400
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					714,286	2,000,000
Proceeds from Issuance of Common Stock | $						$ 3,000,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 1.50
Proceeds from Issuance of Convertible Preferred Stock | $						$ 7,000,000
Private Placement [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						7,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 1,000
Preferred Stock, Redemption Price Per Share (in dollars per share) | $ / shares						2.545
Private Placement [Member] | Series A Convertible Preferred Stock [Member] | Conversion Price if Common Stock Not Trade at 3.15 [Member]
Preferred Stock, Redemption Price Per Share (in dollars per share) | $ / shares						$ 1.50
April 6, 2020 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				5,420,000
Proceeds from Issuance of Common Stock, Gross | $				$ 5,100,000
Share Price (in dollars per share) | $ / shares				$ 0.95
Proceeds from Issuance of Common Stock | $				$ 4,600,000
June 30, 2020 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	6,770,000
Proceeds from Issuance of Common Stock, Gross | $	$ 14,600,000
Share Price (in dollars per share) | $ / shares	$ 2.15		$ 2.15
Proceeds from Issuance of Common Stock | $			$ 13,400,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Warrants (Details) - USD ($)	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Outstanding, number of shares (in shares)	1,592,775	1,074,171	1,592,775
Outstanding, weighted average exercise price (in dollars per share)	$ 2.55	$ 0.50	$ 2.55
Outstanding, weighted average remaining life (Year)	2 years 109 days	2 years 266 days	4 years 36 days	76 days
Outstanding, intrinsic value		$ 880,449	$ 956,012
Issued, number of shares (in shares)	1,749,171	6,459,000
Issued, weighted average exercise price (in dollars per share)	$ 0.50	$ 2.01
Issued, weighted average remaining life (Year)	4 years 127 days	3 years
Issued, intrinsic value	$ 560,199
Exercised, number of shares (in shares)	(57,750)	(1,133,975)
Exercised, weighted average exercise price (in dollars per share)	$ 0.50	$ 0.87
Expired or cancelled, number of shares (in shares)
Expired or cancelled, weighted average exercise price (in dollars per share)
Outstanding , number of shares (in shares)	3,284,196	6,399,196	1,074,171	1,592,775
Outstanding , weighted average exercise price (in dollars per share)	$ 1.49	$ 1.95	$ 0.50	$ 2.55

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Shares-to-be-issued, outstanding (in shares)	2,375,762	2,470,566
Granted in current period (in shares)	363,956	1,392,460
Issued in current period (in shares)	(387,991)	(1,216,680)
Shares-to be issued outstanding (in shares)	2,351,727	2,646,346

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Assumptions Used to Value Warrants at Grant Date (Details)	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2016
Measurement Input, Share Price [Member] | The 2016 Warrants [Member]
Warrants, measurement input		0.83
Measurement Input, Share Price [Member] | The 2016 Warrants [Member] | Minimum [Member]
Warrants, measurement input			0.36
Measurement Input, Share Price [Member] | The 2016 Warrants [Member] | Maximum [Member]
Warrants, measurement input			0.83
Measurement Input, Share Price [Member] | The 2019 Warrants [Member]
Warrants, measurement input	0.33	0.08
Measurement Input, Expected Term [Member] | The 2016 Warrants [Member]
Warrants, measurement input		0.02
Measurement Input, Expected Term [Member] | The 2016 Warrants [Member] | Minimum [Member]
Warrants, measurement input			0.25
Measurement Input, Expected Term [Member] | The 2016 Warrants [Member] | Maximum [Member]
Warrants, measurement input			0.5
Measurement Input, Expected Term [Member] | The 2019 Warrants [Member]
Warrants, measurement input	4.9	4.4
Measurement Input, Price Volatility [Member] | The 2016 Warrants [Member]
Warrants, measurement input		0.86
Measurement Input, Price Volatility [Member] | The 2016 Warrants [Member] | Minimum [Member]
Warrants, measurement input			0.86
Measurement Input, Price Volatility [Member] | The 2016 Warrants [Member] | Maximum [Member]
Warrants, measurement input			1
Measurement Input, Price Volatility [Member] | The 2019 Warrants [Member]
Warrants, measurement input	0.83	0.86
Measurement Input, Expected Dividend Rate [Member] | The 2016 Warrants [Member]
Warrants, measurement input		0	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Warrants [Member]
Warrants, measurement input	0	0
Measurement Input, Exercise Price [Member] | The 2016 Warrants [Member]
Warrants, measurement input		2.55	2.55
Measurement Input, Exercise Price [Member] | The 2019 Warrants [Member]
Warrants, measurement input	0.5	0.5
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Warrants [Member]
Warrants, measurement input		0.0188
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Warrants [Member] | Minimum [Member]
Warrants, measurement input			0.0188
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Warrants [Member] | Maximum [Member]
Warrants, measurement input			0.0209
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Warrants [Member]
Warrants, measurement input	0.023	0.0155
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2016 Warrants [Member]
Warrants, measurement input
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2019 Warrants [Member]
Warrants, measurement input	0.19	0.61
Measurement Input, Number of Shares Granted [Member] | The 2016 Warrants [Member]
Warrants, measurement input		1,512,067	1,512,067
Measurement Input, Number of Shares Granted [Member] | The 2019 Warrants [Member]
Warrants, measurement input	1,749,171	1,691,421

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	9 Months Ended
	Sep. 30, 2020
Percentage of Valuation Allowance	100.00%

Note 11 - Segment and Geograp_3

Note 11 - Segment and Geographic Data (Details Textual)	9 Months Ended
	Sep. 30, 2020
Number of Reportable Segments	2

Note 11 - Segment and Geograp_4

Note 11 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Product sales, net	$ 1,246,110	$ 1,899,821	$ 3,225,170	$ 6,073,580
Operating Income (Loss)	(1,476,728)	(946,734)	(6,258,225)	(2,872,749)
Depreciation and Amortization	16,505	25,418	74,861	76,919
Income (loss) before taxes and equity in earnings of affiliates	(1,477,297)	(2,848,667)	(6,266,952)	(4,725,577)
Total assets	19,945,621		19,945,621		$ 6,556,289
Corporate, Non-Segment [Member]
Operating Income (Loss)	(855,123)	(1,036,541)	(3,928,521)	(2,927,652)
Depreciation and Amortization	15,429	19,044	60,653	57,620
Income (loss) before taxes and equity in earnings of affiliates	(853,834)	(2,937,140)	(3,931,333)	(4,777,690)
Total assets	13,576,619		13,576,619		957,238
Dental Segment [Member]
Product sales, net	1,240,110	1,884,321	3,209,370	6,042,580
Dental Segment [Member] | Operating Segments [Member]
Product sales, net	1,240,110	1,884,321	3,209,370	6,042,580
Operating Income (Loss)	191,235	644,650	(32,624)	1,766,087
Depreciation and Amortization	402	3,950	9,202	11,875
Income (loss) before taxes and equity in earnings of affiliates	190,472	645,442	(35,376)	1,765,475
Total assets	5,391,842		5,391,842		5,008,324
Medical Segment [Member]
Product sales, net	6,000	15,500	15,800	31,000
Medical Segment [Member] | Operating Segments [Member]
Product sales, net	6,000	15,500	15,800	31,000
Operating Income (Loss)	(812,840)	(554,843)	(2,297,080)	(1,711,184)
Depreciation and Amortization	674	2,424	5,006	7,424
Income (loss) before taxes and equity in earnings of affiliates	(813,935)	$ (556,969)	(2,300,243)	$ (1,713,362)
Total assets	$ 977,160		$ 977,160		$ 590,727

Note 11 - Segment and Geograp_5

Note 11 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Product sales, net	$ 1,246,110	$ 1,899,821	$ 3,225,170	$ 6,073,580
Dental Segment [Member]
Product sales, net	1,240,110	1,884,321	3,209,370	6,042,580
Medical Segment [Member]
Product sales, net	6,000	15,500	15,800	31,000
Domestic [Member]
Product sales, net	408,129	896,890	1,067,133	2,721,779
Domestic [Member] | Devices [Member]
Product sales, net	34,657	199,926	35,181	409,529
Domestic [Member] | Handpieces [Member]
Product sales, net	356,566	679,621	994,057	2,250,842
Domestic [Member] | Other Products [Member]
Product sales, net	16,906	17,343	37,895	61,408
Domestic [Member] | Dental Segment [Member]
Product sales, net	408,129	896,890	1,065,133	2,710,679
Domestic [Member] | Dental Segment [Member] | Devices [Member]
Product sales, net	34,657	199,926	35,181	398,729
Domestic [Member] | Dental Segment [Member] | Handpieces [Member]
Product sales, net	356,566	679,621	992,057	2,250,542
Domestic [Member] | Dental Segment [Member] | Other Products [Member]
Product sales, net	16,906	17,343	37,895	61,408
Domestic [Member] | Medical Segment [Member]
Product sales, net			2,000	11,100
Domestic [Member] | Medical Segment [Member] | Devices [Member]
Product sales, net				10,800
Domestic [Member] | Medical Segment [Member] | Handpieces [Member]
Product sales, net			2,000	300
Domestic [Member] | Medical Segment [Member] | Other Products [Member]
Product sales, net
Rest of World [Member]
Product sales, net			2,158,037	3,251,801
Rest of World [Member] | Devices [Member]
Product sales, net	220,694	412,819	502,598	1,108,488
Rest of World [Member] | Handpieces [Member]
Product sales, net	608,000	579,765	1,624,724	2,040,250
Rest of World [Member] | Other Products [Member]
Product sales, net	9,287	10,347	30,715	103,063
Rest of World [Member] | Dental Segment [Member]
Product sales, net			2,144,237	3,231,901
Rest of World [Member] | Dental Segment [Member] | Devices [Member]
Product sales, net	220,694	412,819	494,998	1,100,488
Rest of World [Member] | Dental Segment [Member] | Handpieces [Member]
Product sales, net	602,000	564,265	1,618,524	2,028,750
Rest of World [Member] | Dental Segment [Member] | Other Products [Member]
Product sales, net	9,287	10,347	30,715	102,663
Rest of World [Member] | Medical Segment [Member]
Product sales, net			13,800	19,900
Rest of World [Member] | Medical Segment [Member] | Devices [Member]
Product sales, net			7,600	8,000
Rest of World [Member] | Medical Segment [Member] | Handpieces [Member]
Product sales, net	6,000	15,500	6,200	11,500
Rest of World [Member] | Medical Segment [Member] | Other Products [Member]
Product sales, net				400
International [Member]
Product sales, net	837,981	1,002,931
International [Member] | Dental Segment [Member]
Product sales, net	831,981	987,431
International [Member] | Medical Segment [Member]
Product sales, net	6,000	15,500
CHINA
Product sales, net				100,000
CHINA | Devices [Member]
Product sales, net
CHINA | Handpieces [Member]
Product sales, net				100,000
CHINA | Other Products [Member]
Product sales, net
CHINA | Dental Segment [Member]
Product sales, net				100,000
CHINA | Dental Segment [Member] | Devices [Member]
Product sales, net
CHINA | Dental Segment [Member] | Handpieces [Member]
Product sales, net				100,000
CHINA | Dental Segment [Member] | Other Products [Member]
Product sales, net
CHINA | Medical Segment [Member]
Product sales, net
CHINA | Medical Segment [Member] | Devices [Member]
Product sales, net
CHINA | Medical Segment [Member] | Handpieces [Member]
Product sales, net
CHINA | Medical Segment [Member] | Other Products [Member]
Product sales, net

Note 12 - Concentrations (Detai

Note 12 - Concentrations (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2020USD ($)	Sep. 30, 2019	Dec. 31, 2019
Revenue Benchmark [Member] | Domestic Distributor [Member]
Concentration Risk, Percentage		40.00%
Revenue Benchmark [Member] | International Distributor [Member]
Concentration Risk, Percentage			45.00%
Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage	54.00%		51.00%
Accounts Receivable [Member]
Number of Customers		2
Accounts Receivable [Member] | Domestic Distributor [Member]
Concentration Risk, Percentage				77.00%
Accounts Receivable [Member] | Two Customers [Member]
Accounts Receivable, before Allowance for Credit Loss		$ 720,000
Accounts Receivable [Member] | Milestone China [Member]
Concentration Risk, Percentage		74.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage		60.00%
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage		14.00%

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - USD ($)	Apr. 29, 2020	Feb. 28, 2019	Jan. 31, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jun. 30, 2014
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 308,000		$ 380,000
Director of Clinical Affairs [Member]
Royalty Expense				$ 61,000	$ 92,000	158,000	$ 292,000
Professional Fees				39,000	39,000	117,000	117,000
Accounts Payable, Related Parties				$ 80,000		$ 80,000		390,000
Milestone China [Member]
Equity Method Investment, Ownership Percentage				40.00%		40.00%			40.00%
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party	$ 370,260			$ 373,000	549,000	$ 1,200,000	1,100,000
Due to Related Parties, Total				365,000		365,000		$ 943,000
Consulting Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party				25,000	25,000	75,000	75,000
Consulting Services [Member] | United Systems [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)		285,714
Shares Issued, Price Per Share (in dollars per share)		$ 0.35
Stock Issued During Period, Value, Issued for Services		$ 100,000
Consultant [Member] | Innovest S.p.A. [Member]
Related Party Transaction, Expenses from Transactions with Related Party				$ 20,000	$ 20,000	$ 60,000	$ 60,000
Consulting Services Agreement, Term (Month)			1 year

Note 14 - Commitments (Details

Note 14 - Commitments (Details Textual)	Jan. 01, 2005	Jul. 31, 2020	Aug. 31, 2019USD ($)	Jun. 30, 2015USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Advances on Inventory Purchases					$ 723,084	$ 723,084		$ 710,662
Operating Leases, Monthly Rent Expense				$ 12,522
Operating Lease, Right-of-Use Asset					655,870	655,870		15,977
Operating Lease, Liability, Total					645,341	645,341
Operating Lease, Liability, Current					68,934	68,934		12,072
Operating Lease, Liability, Noncurrent					576,407	576,407
Operating Lease and Finance Lease, Liability, Current								15,977
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability						43,242
Finance Lease, Liability, Total					38,527	38,527
Finance Lease, Liability, Current					7,903	7,903		3,904
Finance Lease, Liability, Noncurrent					$ 30,624	$ 30,624
Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology	2.50%
Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology	5.00%
Copiers Lease Agreement [Member]
Lessee, Finance Lease, Term of Contract (Year)					5 years	5 years
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability						$ 43,242
Office Lease for Headquarter in Livingston, New Jersey [Member]
Area of Rentable Space (Square Foot) | ft²				774
Lessee, Operating Lease, Term of Contract (Year)			7 years
Lessee, Operating Lease, Electric Charge Per Square Foot			$ 2
Lessee, Operating Lease, Electric Payments, Annually			11,130
Office Lease for Headquarter in Livingston, New Jersey [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense			9,275
Office Lease for Headquarter in Livingston, New Jersey [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense			$ 10,898
Purchase Commitment for Devices [Member]
Purchase Commitment, Remaining Minimum Amount Committed					$ 515,284	515,284
Advances on Inventory Purchases					350,311	350,311
Purchase Commitment for Devices Begining in 2020 [Member]
Purchase Commitment, Remaining Minimum Amount Committed					299,000	299,000
Advances on Inventory Purchases					161,000	$ 161,000
Purchase Commitment Number Of Units			100			100
Purchase Commitment For Epidural Disposable Kits Beginning In November 2020 [Member]
Purchase Commitment, Remaining Minimum Amount Committed					30,395	$ 30,395
Advances on Inventory Purchases					$ 21,195	$ 21,195
Purchase Commitment Number Of Units		110				110

Note 14 - Commitments - Lease E

Note 14 - Commitments - Lease Expense (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Cash paid for operating lease liabilities		$ 30,820	$ 39,555	$ 78,904	$ 118,664
Cash paid for finance lease liabilities		2,658		7,622
Right-of-use assets obtained in exchange for new operating lease liabilities (1)	[1]			(663,009)
Property and equipment obtained in exchange for new finance lease liabilities				$ (43,242)
Weighted-average remaining lease term - operating leases (Year)		6 years 182 days	146 days	6 years 182 days	146 days
Weighted-average remaining lease term- finance leases (Year)		4 years 109 days		4 years 109 days
[1]	For the nine months ended September 30, 2019, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2019.

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	2 Months Ended	9 Months Ended		12 Months Ended
	Nov. 16, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2021	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.95			$ 0.50	$ 1.49	$ 2.55
Proceeds from Warrant Exercises		$ 985,763	$ 28,875
Forecast [Member] | Consultant [Member]
Stock Issued During Period, Value, Issued for Services				$ 60,000
First Warrants Exercised Subsequent to June 30, 2020 [Member] | Subsequent Event [Member]
Stock Issued During Period Shares, Warrants Exercised (in shares)	8,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.20
Proceeds from Warrant Exercises	$ 9,600